Baird starts Nuvalent at outperform, cites potential of lead assets [Seeking Alpha]
Nuvalent, Inc. - Class A (NUVL)
NASDAQ:AMEX Investor Relations:
nuvelinc.com/company/investor_relations.html
Company Research
Source: Seeking Alpha
The investment bank said it believes Nuvalent has “built a better mousetrap” with NVL-520 for ROS1+ lung cancer and NVL-655 for ALK+ lung cancer. It has modeled peak sales of $1.2B for previously treated ALK+ and $640M for previously treated ROS1+. “We expect the pivotal studies reading out next year will validate best-in-class profiles, and growing confidence in the significant front-line ALK+ NSCLC opportunity should support further upside," Baird said. It estimated the front-line ALK+ NSCLC market at more than $2B. “We see both lead assets as billion-dollar-plus opportunities, supporting our $105 price target,” Baird added. Recommended For You Recommended For You About NUVL Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
NUVL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVL alerts
High impacting Nuvalent, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
NUVL
News
- Jefferies starts Nuvalent at buy, cites lung cancer drug candidates [Seeking Alpha]Seeking Alpha
- Nuvalent, Inc. (NASDAQ: NUVL) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $97.00 price target on the stock.MarketBeat
- Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024PR Newswire
- Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at Leerink Partnrs from a "market perform" rating to an "outperform" rating.MarketBeat
- Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating. They now have a $110.00 price target on the stock, up previously from $69.00.MarketBeat
NUVL
Earnings
- 11/14/23 - In-Line
NUVL
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- NUVL's page on the SEC website